LABT Lakewood-Amedex Biotherapeutics
$2.22▲ +8.29%
Healthcare
Other
After hours
$2.22▲ +0.00%
Sep 11, 7:46 PM ET
Volume 140.7K
Avg Volume (10D) 2.42M
Key Metrics & Fundamentals
Market Cap
$5.26M
P/E Ratio
–
Div Yield
–%
52W Range
1.66 - 98.20
% vs 50 MA
-4.20%
% vs 200 MA
–%
RSI-14
44.9
MACD Histogram
+0.0500
Beta (1Y vs SPY)
-1.41
Free Cash Flow
-$2.10M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.73M
COGS
–
Operating Exp
$3.79M
Operating Income
-$3.79M
EBIT
-$3.79M
Pretax Income
-$3.77M
Net Income
-$3.77M
EPS (Diluted)
-2.75
Price & Volume History
Loading chart…
Recent News
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · Sep 8, 2026 12:02 PM
LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers
Zacks Small Cap Research · Aug 26, 2026 1:26 PM
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company
NewMediaWire · Aug 25, 2026 9:36 PM
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
PR Newswire · Jul 22, 2026 12:02 PM
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
PR Newswire · Jul 15, 2026 12:02 PM
CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics
Zacks Small Cap Research · Jul 13, 2026 4:35 PM
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
PR Newswire · Jul 7, 2026 12:02 PM
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
GlobeNewswire · Jun 26, 2026 12:35 PM
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
PR Newswire · Jun 25, 2026 12:02 PM
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
GlobeNewswire · Jun 23, 2026 12:35 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See LABT's money flow as a full page
Social Sentiment
No Reddit posts found for LABT.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.